Little vascular plasters

Trigen Holdings AG sees its PR-15 as a bandage that moves through the bloodstream patching up collagen exposed in damaged vascular walls. The company thinks the platelet adhesion inhibitor may have less severe bleeding side effects than marketed antiplatelet therapies and have the potential to replace treatment with GPIIb/IIIa inhibitors.

Last week, Trigen (Munich, Germany) exclusively licensed IP from Millennium Pharmaceuticals Inc. (MLNM, Cambridge, Mass.) covering the platelet surface receptor

Read the full 696 word article

How to gain access

Continue reading with a
two-week free trial.